The day of plenary is the most enjoyable in my view including at ISSCR 2015 on the first day with a Yamanaka talk. You don’t need to make the choice between sessions and the judgement on the viability of shifting sessions versus staying put and listening to the slightly less relevant. ISSCR 2015 plenary was, […]
Overview of Yamanaka Talk at #ISSCR2015 by Heather Main Read More »
The publicly available medical literature database PubMed can be found here. I recommend if you are doing a search for a stem cell paper on a disease of you interest that you plug into the search box the following: stem cells[title] AND XXXX In this case delete XXXX and put in the name of the
Search for a paper Read More »
A decade ago I wrote an article in the journal Nature Biotechnology about the rise of a new gene editing technology called zinc finger nucleases (ZNF). It was one of those “drumbeat” discoveries: at the time, my sense was it would revolutionize how we deliver genes to cells and tissues, and profoundly change the way
Guest Post by Chris Scott–The Great CRISPR Controversy: What’s Next? Read More »
What is the “proper” amount of freedom of choice for patients in medicine? What if the treatments in question are experimental and come with their own baggage of associated risks, personal costs, and potential costs to society? More broadly, do patients have a fundamental right to medical choice? These questions seem particularly appropriate today on
Do Patients Have a Fundamental Right to Choice? Read More »
Statins have been hailed as some of the best drugs ever. Given the massive, deadly prevalence of cardiovascular disease, some have even semi-jokingly talked about putting these drugs in the water supply for public health. The growing evidence (e.g. this story) that statins might significantly aid in prevention, delayed progression, or even post-treatment delay of
Statins dilemma: heart & cancer benefits, but diabetes risk Read More »
Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy
Bioheart on the edge in 2015? Read More »
The paper that came out Wednesday from a research group in China reporting the first genetic modification of human embryos has sparked a lot of discussion. Some concerns about this paper have surfaced. 2-day review? The paper (HT to John Borghi) was in review only from March 30-April 1 — so at most 48 hours. Really? That certainly
Concerns surface on Chinese paper on genetic modification of human embryos Read More »
The Juan Carlos Izpisua Belmonte group published a Cell paper today on using gene editing to reverse mutations associated with human mitochondrial disease. The paper is Reddy, et al. and is entitled, “Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing”. The authors report success using TALEN-based gene editing or mitochondrial-direct restriction enzyme (mito-ApaLI)
Juan Carlos Izpisua Belmonte Cell Paper on Gene Editing for Mitochondrial Disease Read More »
Rumors have been flying for months that researchers in China and possibly elsewhere were shopping papers around at high-profile journals that reported gene editing and genetic modification of human embryos. Update: apparently this paper (HT to @JohnBorghi) was only reviewed for 2 days (see image at bottom of post), raising major concerns about the depth of
Researchers in China make genetically modified human embryos Read More »
I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem
Interview with Bioheart CSO, Kristin Comella including on FDA Read More »